Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.22), $0.05 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $125 thousand versus the consensus estimate of $339.28 thousand.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.